期刊
JOURNAL OF FUNGI
卷 9, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/jof9010042
关键词
antifungal peptides; Aspergillus; antifungal resistance; Aspergillus fumigatus; allergic bronchopulmonary aspergillosis (ABPA)
The global prevalence of fungal infections, particularly aspergillosis which was previously limited to immunosuppressed individuals, is on the rise. Aspergillus fumigatus, resistant to antimycotics such as fluconazole, poses a public health threat by causing allergic bronchopulmonary aspergillosis. Antifungal peptides, by forming pores in membranes through electrostatic interactions with phospholipids and inducing cell death as well as inhibiting protein synthesis and replication, offer a viable alternative. Engineering these peptides using nanotechnology can enhance efficacy, reduce dosages, and minimize immune responses.
The prevalence of fungal infections is increasing worldwide, especially that of aspergillosis, which previously only affected people with immunosuppression. Aspergillus fumigatus can cause allergic bronchopulmonary aspergillosis and endangers public health due to resistance to azole-type antimycotics such as fluconazole. Antifungal peptides are viable alternatives that combat infection by forming pores in membranes through electrostatic interactions with the phospholipids as well as cell death to peptides that inhibit protein synthesis and inhibit cell replication. Engineering antifungal peptides with nanotechnology can enhance the efficacy of these therapeutics at lower doses and reduce immune responses. This manuscript explains how antifungal peptides combat antifungal-resistant aspergillosis and also how rational peptide design with nanotechnology and artificial intelligence can engineer peptides to be a feasible antifungal alternative.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据